Literature DB >> 7632119

Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features.

R E Gur1, P D Mozley, S M Resnick, L H Mozley, D L Shtasel, F Gallacher, S E Arnold, J S Karp, A Alavi, M Reivich.   

Abstract

BACKGROUND: Functional neuroimaging can elucidate brain dysfunction in schizophrenia. The frontal, temporolimbic, and diencephalic regions have been implicated. There is a lack of prospective samples of first-episode and previously treated patients followed up longitudinally.
METHODS: Patients and controls (42 per group) were studied. Positron emission tomography with flurodeoxyglucose, cross-registered with magnetic resonance imaging, measured metabolism. Scales assessed clinical features, premorbid adjustment, and outcome.
RESULTS: There were no differences between groups in whole-brain metabolism or regional ratios or in anterior-posterior gradients, but left midtemporal metabolism was relatively higher in patients. This was pronounced in the negative and Schneiderian and absent in the paranoid subtypes. Higher metabolism and lower relative left hemispheric values were associated with better premorbid adjustment and outcome. A higher subcortical-cortical gradient was noted in first-episode patients.
CONCLUSIONS: There are no resting metabolic abnormalities in any brain region, but abnormal gradients are evident. These vary in subtypes, and laterality is associated with functioning. The results support the hypothesis of temporolimbic disturbance in schizophrenia that is all ready present at the onset of illness.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7632119     DOI: 10.1001/archpsyc.1995.03950200047013

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  22 in total

Review 1.  Scent of a disorder: olfactory functioning in schizophrenia.

Authors:  Paul J Moberg; Bruce I Turetsky
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 3.  Hippocampal function, declarative memory, and schizophrenia: anatomic and functional neuroimaging considerations.

Authors:  Alison R Preston; Daphna Shohamy; Carol A Tamminga; Anthony D Wagner
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

4.  Odor identification, eye tracking and deficit syndrome schizophrenia.

Authors:  Dolores Malaspina; Eliza Coleman; Raymond R Goetz; Jill Harkavy-Friedman; Cheryl Corcoran; Xavier Amador; Scott Yale; Jack M Gorman
Journal:  Biol Psychiatry       Date:  2002-05-15       Impact factor: 13.382

5.  Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.

Authors:  Mia Thompson Ray; Cynthia Shannon Weickert; Eugene Wyatt; Maree J Webster
Journal:  J Psychiatry Neurosci       Date:  2011-05       Impact factor: 6.186

Review 6.  GABAergic mechanisms of hippocampal hyperactivity in schizophrenia.

Authors:  Stephan Heckers; Christine Konradi
Journal:  Schizophr Res       Date:  2014-10-18       Impact factor: 4.939

Review 7.  Imaging phenotypes and genotypes in schizophrenia.

Authors:  Jessica A Turner; Padhraic Smyth; Fabio Macciardi; James H Fallon; James L Kennedy; Steven G Potkin
Journal:  Neuroinformatics       Date:  2006

Review 8.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

9.  Mitochondrial enzymes in schizophrenia.

Authors:  Parvesh Bubber; Jicheng Tang; Vahram Haroutunian; Hui Xu; Kenneth L Davis; John P Blass; Gary E Gibson
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

10.  Expression analyses of the mitochondrial complex I 75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential biomarker for early onset schizophrenia.

Authors:  Regina Taurines; Johannes Thome; J Catharina Duvigneau; Sarah Forbes-Robertson; Liya Yang; Karin Klampfl; Jasmin Romanos; Sabine Müller; Manfred Gerlach; Claudia Mehler-Wex
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-11-06       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.